Mylan Must Face Many Of Investors' EpiPen Fraud Claims
EpiPen maker Mylan NV must face a trimmed-down proposed securities fraud class action accusing it of misleading investors about how it was allegedly overcharging Medicaid for EpiPen purchases and engaging in...To view the full article, register now.
Already a subscriber? Click here to view full article